TEVA · Teva Pharmaceutical Industries Ltd.
The AI's read
The approval gives Teva another way to use a treatment it recently acquired. A 12-week study covered 1,160 agitation episodes among 102 patients, and none stopped treatment because of side effects. Patients reported sleepiness, dry mouth, dizziness, and mouth sensations. Teva also paid $57.5 million upfront and may pay up to $67.5 million more. The new at-home use and study results make this a positive development despite those costs and side effects.